<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062659</url>
  </required_header>
  <id_info>
    <org_study_id>TCell</org_study_id>
    <nct_id>NCT01062659</nct_id>
  </id_info>
  <brief_title>Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients</brief_title>
  <official_title>Characterization of Cellular Immune Responses in the Liver in Patients With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to persist in the liver, HCV has numerous nonspecific and specific strategies to
      overcome the immunity of the host. The crucial step in the establishment of viral persistence
      and chronic hepatitis is the avoidance of specific antiviral cellular immune response in the
      liver. Treatment with pegylated interferon alpha (IFNα) in combination with ribavirin (RBV)
      is the standard therapy for chronic hepatitis C is. The response to IFNα / RBV therapy
      depends on the effective cellular antiviral immune response in the liver. The understanding
      of the interaction between HCV and cellular immune response is important for the effective
      use of existing diagnostic techniques, the Individual control and adjustment of the current
      therapeutic approaches and the development of future therapeutic and immunization strategies.
      In this study, the investigators want to investigate cellular Immune responses in the liver
      of HCV infected patients and characterize the influence of these immune responses to the
      response to IFNα / RBV therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Liver Diseases</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>chronic Hepatitis C</arm_group_label>
    <description>Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patient with established chronic hepatitis C presented to the liver unit of the
        outpatient clinic how are eligible to antiviral therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  proven chronic hepatitis C

          -  aged between 18 and 65

          -  willingness to give written informed consent to the study protocol

        Exclusion Criteria:

          -  history of having received any IFN, PEG-IFN or RBV

          -  not eligible for antiviral treatment with peginterferon and ribavirin by standard of
             care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietmar M Klass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Dietmar M. Klass</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>hepatitis C virus</keyword>
  <keyword>CHC</keyword>
  <keyword>chronic hepatitis c</keyword>
  <keyword>interferon</keyword>
  <keyword>ribavirin</keyword>
  <keyword>Hepatitis, Viral, Human</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>peginterferon alfa-2a</keyword>
  <keyword>peginterferon alfa-2b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

